NCT03564548View on ClinicalTrials.gov

Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

April 30, 2022

Conditions
CancerBreakthrough Cancer Pain
Interventions
DRUG

PPP001

Group assigned to PPP001

DRUG

Morphine sulfate or Hydromorphone or Oxycodone

Group assigned to morphine sulfate or hydromorphone or oxycodone

Trial Locations (1)

08009

RECRUITING

HRI, Berlin

Sponsors

Lead Sponsor

Tetra Bio-Pharma
All Listed Sponsors
collaborator

Cognitive Research Corporation

INDUSTRY

lead

Tetra Bio-Pharma

INDUSTRY